<DOC>
	<DOCNO>NCT01104246</DOCNO>
	<brief_summary>The study evaluate pharmacokinetics testosterone transdermal system steady-state hypogonadal men .</brief_summary>
	<brief_title>Dose Titration Investigation Pharmacokinetics Testosterone Transdermal Systems Hypogonadal Men</brief_title>
	<detailed_description>Subjects receive testosterone 4 week . Based single morning testosterone measurement perform end Week 1 , dosage titrate next dose level maintain testosterone level normal range . At end 4 week treatment , pharmacokinetic profile total testosterone metabolite obtain .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Males good general health , 18 year age old . Have previously document testosterone deficiency . Willing able comply requirement protocol . Have history intolerance Androderm testosterone product . Prostate specific antigen ( PSA ) level â‰¥ 4.0 ng/mL Prostate cancer severe benign prostatic hypertrophy ( BPH ) Have significant abnormality physical examination screening . Have current dermatological disease , skin damage blemish . Have participate investigational drug study within 30 day prior screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Hormone replacement therapy</keyword>
</DOC>